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Abstract
Purpose Trastuzumab emtansine (T-DM1) is an antibody–
drug conjugate comprising trastuzumab and DM1, a micro-
tubule polymerization inhibitor, covalently bound via a
stable thioether linker. To characterize the pharmacokinet-
ics (PK) of T-DM1 in patients with human epidermal
growth factor receptor 2 (HER2)-positive metastatic breast
cancer, data from four studies (TDM3569g, TDM4258g,
TDM4374g, and TDM4688g) of single-agent T-DM1
administered at 3.6 mg/kg every 3 weeks (q3w) were
assessed in aggregate.
Methods Multiple analytes—T-DM1, total trastuzumab
(TT), DM1, and key metabolites—were quantiWed using
enzyme-linked immunosorbent assays or liquid chromatog-
raphy tandem mass spectrometry. PK parameters of
T-DM1, TT, and DM1 exposure were calculated using
standard noncompartmental approaches and correlated
to eYcacy (objective response rate) and safety (platelet
counts, hepatic transaminase concentrations). Immunoge-
nicity was evaluated by measuring anti-therapeutic antibod-
ies (ATA) to T-DM1 after repeated dosing using validated
bridging antibody electrochemiluminescence or enzyme-linked
immunosorbent assays.
Results PK parameters for T-DM1, TT, and DM1 were
consistent across studies at cycle 1 and steady state. T-DM1
PK was not aVected by residual trastuzumab from prior
therapy or circulating extracellular domain of HER2. No
signiWcant correlations were observed between T-DM1
exposure and eYcacy, thrombocytopenia, or increased con-
centrations of transaminases. Across the studies, ATA for-
mation was detected in 4.5% (13/286) of evaluable patients
receiving T-DM1 q3w.
Conclusions The PK proWle of single-agent T-DM1
(3.6 mg/kg q3w) is predictable, well characterized, and
unaVected by circulating levels of HER2 extracellular
domain or residual trastuzumab. T-DM1 exposure does not
correlate with clinical responses or key adverse events.
Keywords Trastuzumab emtansine · T-DM1 · 
Breast cancer · HER2 · Antibody–drug conjugate
Introduction
Human epidermal growth factor receptor 2 (HER2; also
known as ErbB2, neu, or p185HER2) is a member of the epi-
dermal growth factor receptor family of transmembrane
receptors [1]. Gene ampliWcation and receptor overexpres-
sion of HER2 are observed in approximately 20–25% of
human breast cancers [1, 2]. HER2 overexpression is an
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adverse prognostic factor associated with aggressive tumor
growth and poor clinical outcomes in patients with breast
cancer [1–3].
Trastuzumab is a humanized immunoglobulin G1 (IgG1)
monoclonal antibody that targets the HER2 extracellular
domain (ECD). Trastuzumab in combination with chemo-
therapy is the standard of care for patients with early or
metastatic HER2-positive breast cancer [3–6]. DM1, a
derivative of maytansine, is a highly potent microtubule
polymerization inhibitor [7–9]. It competes with vinca alka-
loids for binding on the beta subunit of tubulin. In studies
of HER2-positive and HER2-negative cell lines, maytan-
sine derivatives (including DM1) are 25- to 500-fold more
potent than paclitaxel [10–12] and 100–4,000 times more
potent than doxorubicin [10].
Trastuzumab emtansine (T-DM1) is an antibody–drug
conjugate in the clinical development for the treatment of
HER2-positive cancers [13–16]. Antibody–drug conjugates
are designed to target the delivery of a highly potent cytotoxic
agent to tumor cells [17–19], thereby creating a more favor-
able therapeutic window for cytotoxic agents than would be
achieved by the administration of free cytotoxic agent.
T-DM1 comprises trastuzumab linked to DM1 (0–8
DM1 molecules per antibody) using the heterobifunctional
reagent succinimidyl-trans-4-[maleimidylmethyl] cyclo-
hexane-1-carboxylate, a stable thioether linker that binds
primarily to antibody lysine residues [7–9]. An average of
3.5 DM1 moieties is linked to each trastuzumab molecule
in T-DM1 [16].
T-DM1 binds to HER2 with an aYnity similar to that of
trastuzumab [10]. After internalization of the receptor–
T-DM1 complex, intracellular release of DM1-containing
moieties from T-DM1 is thought to occur via lysosomal deg-
radation [20], resulting in the inhibition of cell division and
cell growth and eventually culminating in cell death [16, 17].
Moreover, T-DM1 has been shown to preserve the antitumor
properties of trastuzumab, including the inhibition of HER2
signaling and the Xagging of HER2-overexpressing cells for
antibody-dependent cellular cytotoxicity [10, 16]. Therefore,
T-DM1 is believed to have multiple antitumor eVects beyond
its role in target-speciWc drug delivery.
To date, four studies have evaluated single-agent T-DM1
at its maximum tolerated dose (MTD) of 3.6 mg/kg given
every 3 weeks (q3w) in pretreated patients with HER2-
positive metastatic breast cancer (MBC). The Wrst-in-
human phase I study (TDM3569g) established the MTD
and identiWed transient grade 4 thrombocytopenia as the
dose-limiting toxicity (DLT) at 4.8 mg/kg [13]. Results
from studies TDM4258g and TDM4374g, two phase II
studies of T-DM1 3.6 mg/kg q3w for patients with HER2-
positive MBC who had received prior HER2-directed ther-
apies, demonstrated overall response rates of 25.9% and
34.5%, respectively [14, 15]. The durations of responses in
these latter studies are not yet estimable because of the
short follow-up to date. The phase II study TDM4688g
evaluated the eVects of single-agent T-DM1 on the duration
of corrected QT (QTc) interval; the QTc results from this
study have recently been reported [21].
To assess the clinical pharmacology of T-DM1, perti-
nent data from these four single-arm studies were consoli-
dated. This report summarizes all of the pharmacokinetic
(PK) data obtained from the completed single-arm studies
of T-DM1 in patients with HER2-positive MBC.
Methods
Studies
The TDM3569g, TDM4258g, TDM4374g, and TDM4688g
studies were carried out in accordance with approval by the
relevant institutional review boards, and all patients pro-
vided written informed consent before participating in each
study. Patients in the phase I study had previously received
a trastuzumab-containing chemotherapy regimen, and
patients in the phase II studies had received a trastuzumab-
and/or a lapatinib-containing chemotherapy regimen in the
metastatic setting and had progressed on their last treatment
[13–15, 21]. In all studies, patients on the q3w regimen
received T-DM1 as a 90-min intravenous infusion in cycle
1 and over 30–60 min in later cycles. Patients could not
have received trastuzumab within 21 days of enrollment.
The primary objectives of the TDM3569g phase I dose-
escalation study were to assess the safety, tolerability, and
3-week-cycle PK of T-DM1 administered by intravenous
infusion on both a q3w and weekly dosing schedule in
patients with HER2-positive MBC who had received trast-
uzumab previously (Table 1). The dose levels evaluated in
the phase I study for the q3w regimen were 0.3 (n =3 ) ,
0.6 (n =1 ) ,  1 . 2  ( n =1 ) ,  2 . 4  ( n = 1), 3.6 (n = 15), and 4.8
(n =3 )  m g / k g .
The primary objectives of TDM4258g, a phase II study,
were the assessment of the objective response rate, safety,
and tolerability of T-DM1 3.6 mg/kg q3w in patients with
HER2-positive MBC who had progressed while receiving
HER2-directed therapy and who had received prior chemo-
therapy for metastatic disease [14]. The primary objectives
of TDM4374g, also a phase II study, were the same, but all
patients had received prior therapy with trastuzumab, lapat-
inib, an anthracycline, a taxane, and capecitabine [15].
Characterization of the T-DM1 PK proWle after single and
multiple cycles was a secondary objective in the TDM4258g
and TDM4374g studies.
The primary objective of the ongoing TDM4688g study is
the evaluation of the eVects of T-DM1 at 3.6 mg/kg q3w (the
MTD for the q3w regimen) on the duration of the QTcCancer Chemother Pharmacol (2012) 69:1229–1240 1231
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interval [21]. PK analysis is a secondary objective. An addi-
tional exploratory objective is to detect and quantify the
catabolites MCC-DM1 and Lys-MCC-DM1 in patients’
plasma samples; these catabolites were Wrst identiWed in pre-
clinical studies as potentially relevant catabolites of T-DM1.
Assays for T-DM1, total trastuzumab, DM1, MCC-DM1, 
and Lys-MCC-DM1
Given the biochemical structure and complexity of T-DM1,
multiple analytes were measured across the four studies to
characterize the PK, including (but not limited to) the
primary analyte, T-DM1, and other analytes such as total
trastuzumab (TT; T-DM1 conjugate plus unconjugated
trastuzumab) and DM1 (cytotoxic agent). T-DM1 and TT
concentrations in serum were quantiWed using validated
enzyme-linked immunosorbent assays (ELISAs) (described
in Krop et al. [13]). DM1 concentrations in plasma were
determined by Xendo Drug Development B.V. (Groningen,
the Netherlands) using a validated liquid chromatography
tandem mass spectrometry (LC–MS/MS) method developed
by Genentech USA [13].
A LC–MS/MS assay was developed for exploratory anal-
ysis of catabolites MCC-DM1 and Lys-MCC-DM1 at
Genentech. These catabolites were extracted from plasma by
protein precipitation. The assay had a lower limit of quantiW-
cation of 1.95 nM (1.90 ng/mL) and 0.976 nM (1.08 ng/mL)
for MCC-DM1 and Lys-MCC-DM1, respectively.
Cross-study PK analyses
Noncompartmental analyses were conducted wherever pos-
sible. For patients with evaluable PK data, standard non-
compartmental methods were used to calculate parameters
at cycles 1 and 3 or 4 (at steady state), using WinNonLin®
5.2.1 in the Pharsight® Knowledgebase Server™.
Data from studies TDM3569g, TDM4258g, and
TDM4374g were included in the population PK analysis,
whereas the noncompartmental analysis (NCA) was con-
ducted individually for each of the four studies. Population
PK was best described by a linear two-compartment model,
as described by Gupta et al. [22].
Assessment of exposure–eYcacy and exposure–safety 
relationships
The relationships between T-DM1, TT, and DM1 exposure
(area under the curve [AUC], maximum concentration
[Cmax], and minimum concentration [Cmin] for T-DM1 and
TT; Cmax for DM1) and eYcacy and safety were evaluated.
For exposure–eYcacy analyses, relationships between
Bayesian post hoc PK parameter estimates obtained from
Table 1 Summary of study designs and pharmacokinetic (PK) sampling schedules for four single-agent studies of trastuzumab emtansine
In all studies, the analytes measured were T-DM1, total trastuzumab, and DM1; incidence of anti-therapeutic antibodies to T-DM1 was also exam-
ined
A population PK analysis was conducted using T-DM1 PK data for all studies except TDM4688g
HER2 human epidermal growth factor receptor 2; MBC metastatic breast cancer; NCA noncompartmental analysis; PK pharmacokinetic; q3w
every 3 weeks; QTc corrected QT; T-DM1 trastuzumab emtansine
a The earliest a patient could begin treatment with T-DM1 in combination with pertuzumab was cycle 4, day 1, after all PK samples for single-
agent T-DM1 had been obtained in cycle 3. Pertuzumab dose: 840-mg loading dose, followed by 420 mg q3w for 1 year
Study No. of 
enrolled 
patients
Prior therapies required 
for eligibility
T-DM1 doses 
and regimens
PK sampling
TDM3569g, 
phase I
q3w: n = 24 Trastuzumab q3w: 0.3, 0.6, 1.2, 2.4, 3.6, 
and 4.8 mg/kg
Intensive sampling in cycle 1; 
peak/trough PK sampling in 
subsequent cycles; NCA of PK data
TDM4258g, 
phase II
112 ¸1 HER2-directed therapy 
and ¸ 1 chemotherapy for MBC
3.6 mg/kg q3w Frequent sampling in cycles 
1 and 4 for NCA of PK data; 
peak/trough PK sampling in 
subsequent cycles
TDM4374g, 
phase II
110 Trastuzumab, lapatinib, capecitabine, 
a taxane, an anthracycline;
¸ 2 HER2-directed 
therapies for MBC
3.6 mg/kg q3w Frequent sampling in cycles 
1 and 4 for NCA of PK; 
peak/trough PK sampling in 
subsequent cycles
TDM4688g, 
phase II
51 Trastuzumab T-DM1 at up to 3.6 mg/kg 
q3w for 1 yeara
Frequent sampling in cycles 
1 and 3 for NCA of PK data; 
QTc assessment pre- and 
post-T-DM1 dosing1232 Cancer Chemother Pharmacol (2012) 69:1229–1240
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the population PK analysis [22] and objective responses
were assessed in patients receiving T-DM1 in TDM4258g
and TDM4374g. Similar assessments were conducted with
NCA parameter estimates obtained using TT and DM1 PK
parameters. Data from dose-escalation and QTc studies
were not used for exposure–eYcacy analyses.
For exposure–safety analyses, correlations between
T-DM1 exposure and levels of aspartate aminotransferase/
alanine aminotransferase (AST/ALT) and platelets were
assessed in patients treated with T-DM1 in TDM3569g,
TDM4258g, and TDM4374g. Post hoc estimates of T-DM1
exposure (AUC) obtained from population PK analysis
were stratiWed into four quartiles, and time courses of these
laboratory assessments (Wfth and ninety-Wfth percentiles,
and individual data below the Wfth percentile for platelet
counts and above the ninety-Wfth percentile for hepatic
enzyme levels) were plotted across treatment cycles. In
addition, T-DM1 exposure was compared in patients with
and without post-dose grade ¸3 transaminase elevations
and/or thrombocytopenia.
Anti-therapeutic antibodies to T-DM1
Immunogenicity of T-DM1 was evaluated by measuring
ATA responses to T-DM1 after repeated dosing in the four
studies. ATA to T-DM1 were assessed in serum samples
before the Wrst T-DM1 dose and after subsequent T-DM1
doses, using a validated bridging antibody electrochemi-
luminescence assay (Bioveris®, San Diego, CA) in
TDM3569g and TDM4258g and by using a validated
ELISA (biotin- and digoxigenin-labeled T-DM1) in
TDM4374g and TDM4688g. Samples were further analyzed
by competitive-binding immunodepletion with T-DM1 and
trastuzumab to conWrm and characterize the ATA response.
In addition, titer values were generated for positive sam-
ples. ATA-evaluable patients were those with at least one
post-dose ATA sample. The ATA rate was deWned as any
patient with a positive response at any post-treatment time
point divided by the total number of ATA-evaluable
patients. Safety and eYcacy implications, if any, were
assessed for ATA-positive patients.
Results
Summaries of study designs, numbers of patients, and data
sampling for TDM3569g, TDM4258g, TDM4374g, and
TDM4688g are provided in Table 1. Baseline demographic
and pathophysiologic characteristics were similar among
the 288 patients who received 3.6 mg/kg q3w in the four
studies (Table 2).
The concentration–time proWles and key PK parameters
for the T-DM1 conjugate following a q3w regimen across
multiple dose levels in the phase I dose-escalation study are
shown in Fig. 1a. Individual concentration–time curves for
T-DM1 3.6 mg/kg q3w (MTD) after cycle 1 and at steady
state for each phase II study are shown in Fig. 1b. Mean
combined concentration–time proWles for T-DM1 conju-
gate, TT (a measure of T-DM1 conjugate plus unconju-
gated trastuzumab), and DM1 are shown in Fig. 1c.
Table 2 Demographic and baseline disease characteristics for patients enrolled in studies TDM3569g (3.6-mg/kg cohort), TDM4258g,
TDM4374g, and TDM4688g
ECD extracellular domain; HER2 human epidermal growth factor receptor 2; N/A not available
a n = 287 patients
b Final data for patients in study TDM4688g were not available; n = 237 patients
Baseline characteristics Median (range)
TDM3569g 
(n = 15)
TDM4258g 
(N = 112)
TDM4374g 
(N = 110)
TDM4688g 
(N =5 1 )
All studies 
(N =2 8 8 )
Age (y) 50 (35–65) 54.5 (33–82) 52.5 (34–77) 52 (34–85) 53 (33–85)
Weight (kg) 65.2 (49.9–93.8) 70.0 (37.7–137) 69.7 (38.5–136) 67.2 (44–105) 69.1 (37.7–137)
Height (cm) 164 (146–173) 163 (128–178) 163 (145–188) 165 (145–181) 163 (128–188)a
Body mass index (kg/m2) 26.1 (16.7–32.8) 26.4 (14.7–52.9) 26.1 (17.1–44.1) 26.1 (17.3–42.4) 26.1 (14.7–52.9)a
Body surface area (m2) 1.70 (1.48–2.05) 1.76 (1.33–2.39) 1.76 (1.29–2.40) 1.76 (1.38–2.14) 1.76 (1.29–2.40)a
Aspartate aminotransferase (IU/L) 28 (14–100) 32.8 (13.5–227) 29.3 (13.5–140) N/A 30.8 (13.5–227)b
Alanine aminotransferase (IU/L) 26.5 (9.5–173) 29.6 (8–111) 24 (9–170) N/A 26 (8–173)b
Platelet count (103/L) 243 (143–354) 263 (127–569) 249 (0.2–886) N/A 252 (112–886)b
Circulating HER2 ECD (ng/mL) 24 (6.3–86.8) 30.1 (5–560) 30.1 (5.9–560) N/A 30.1 (5–560)b
Trastuzumab (g/mL) 6.2 (0.04–72.9) 0.04 (0.04–66.9) 0.11 (0.04–122) 1.88 (0–148) 0.05 (0–148)Cancer Chemother Pharmacol (2012) 69:1229–1240 1233
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Relevant NCA estimates for the PK parameters Cmax,
AUC, terminal half-life (t½), steady-state volume of dis-
tribution (Vss), and clearance are summarized in Table 3
for T-DM1, TT, and DM1 in patients who received
T-DM1 at a dose of 3.6 mg/kg q3w in the phase I and II
studies.
Phase I study results
The dose levels evaluated in the phase I dose-escalation
study for the q3w regimen ranged from 0.3 to 4.8 mg/kg.
For q3w T-DM1 dosing, systemic exposure of T-DM1, as
measured using Cmax and AUC, increased linearly with
Fig. 1 a Serum trastuzumab emtansine (T-DM1) concentration–time
curves and pharmacokinetic parameters by dose level in the T-DM1
dose-escalation study TDM3569g after every-3-week (q3w) dosing.
b Concentration–time curves for T-DM1 in cycle 1 and at steady state
after T-DM1 dosing in TDM4258g, TDM4374g, and TDM4688g.
c Mean concentration proWles combining three phase II studies
(TDM4258g, TDM4374g, and TDM4688g) after Wrst dose of T-DM1.
AUCinf, area under the curve from time 0 extrapolated to inWnity; Cmax,
maximum concentration; t½, terminal half-life; TT, total trastuzumab
(T-DM1 plus unconjugated trastuzumab); Vss, steady-state volume of
distribution
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(mg/kg) q3w
0.3 (n=3)
0.6 (n=1) 
1.2 (n=1)
2.4 (n=1)
3.6 (n=15)
4.8 (n=3)
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(µg/mL)
9.63 (1.73)
13.3
20.3
76.3
76.2 (19.1)
130 (8)
AUCinf
(day ￿ µg/mL)
14.5 (3.4)
24.5
42.9
330
300 (66)
673 (12)
Mean (standard deviation)
Elimination 
t1/2 (day)
1.3 (0.2)
1.3
1.3
2.2
3.1 (0.7)
4.1 (0.7)
Vss
(mL/kg)
35.7 (7.5)
43.8
51.8
30.7
58.4 (12.4)
41.2 (6.2)
Clearance
(mL/day/kg)
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increasing doses ¸2.4 mg/kg (see Fig. 1a). Higher T-DM1
clearance was observed at doses of ·1.2 mg/kg, with mean
clearance values ranging from 21.1 to 27.8 mL/day/kg.
Thus, linearity was established for doses ¸2.4 mg/kg. The
assessment of dose linearity was limited by the number of
patients evaluated per dose level, especially at doses
<3.6 mg/kg. After T-DM1 dosing, TT concentrations
declined more slowly than the levels of T-DM1 did. Mean
concentrations of DM1 were consistently low (mean,
4.57 § 1.33 ng/mL) and declined to below the lower limit
of quantiWcation within a few days after dosing.
Phase II study results
All PK parameters (Cmax, AUC, t½,  Vss, and clearance) for
serum T-DM1, serum TT, and plasma DM1 were consistent at
cycle 1, as well as at steady state (cycles 3 or 4), across studies.
No signiWcant accumulation of T-DM1 was observed with
q3w dosing in any of the studies (see Fig. 1b). Across the stud-
ies, TT had a longer t½ than that of T-DM1. T-DM1 PK
parameters were not aVected by baseline trastuzumab levels or
by baseline HER2 ECD. In all three phase II studies, plasma
DM1 concentrations were low, with no observed accumulation
over treatment cycles. The highest reported concentration of
DM1 was 25 ng/mL in study TDM4374g; in the majority of
samples, especially at later time points, the DM1 concentration
was below the lower limit of quantiWcation of 0.737 ng/mL. A
consistently low DM1 exposure after T-DM1 administration
was observed immediately after dosing.
The average Cmax of DM1 was 5.35 § 2.03, 5.36 § 2.56,
and 5.42 § 1.62 ng/mL in TDM4258g, TDM4374g, and
TDM4688g, respectively.
In study TDM4688g, patient plasma was sampled and
analyzed for the T-DM1 catabolites Lys-MCC-DM1 and
MCC-DM1 in addition to T-DM1, TT, and DM1. At 1 h
after infusion in cycle 1, the mean concentrations of
MCC-DM1 (34.4 ng/mL; range, 6.47–122 ng/mL) and Lys-
MCC-DM1 (1.35 ng/mL; range 1.25–1.45 ng/mL) were low.
Similar mean values were seen 1 h after infusion in cycle 3.
No signiWcant accumulation was observed in systemic circu-
lation for the linker/DM1-containing catabolites of T-DM1.
Exposure–eYcacy relationship
T-DM1 exposures (AUC and Cmax) were generally similar
among patients with an objective response (i.e., a complete
response or a partial response), progressive disease, or stable
disease (Fig. 2a, b). No signiWcant correlations were observed
between activity (as measured by objective response and
Response Evaluation Criteria in Solid Tumors v1.0) and
T-DM1 exposure following dosing at 3.6 mg/kg q3w across
the phase II studies (TDM4258g and TDM4374g).
Table 3 Serum trastuzumab emtansine (T-DM1), serum total trastuzumab (TT), and plasma DM-1 pharmacokinetic (PK) parameters for patients
in studies TDM3569g (3.6-mg/kg cohort), TDM4258g, TDM4374g, and TDM4688g
AUCinf  area under the serum concentration versus time curve from time 0 extrapolated to inWnity; Cmax maximum observed concentration; PK
pharmacokinetic; Vss volume of distribution at steady state; t1/2 terminal half-life
a Number of patients with at least one PK parameter evaluable
b Plasma DM1 concentrations were below the limit of quantiWcation at the majority of time points and, therefore, no formal PK analysis was
possible
Analyte Study (no. 
of patientsa)
Mean (standard deviation)
Cmax 
(g/mL)
AUCinf 
(day  g/mL)
t1/2 (day) Vss (mL/kg) Clearance 
(mL/day/kg)
Serum T-DM1 TDM3569g (n = 15) 76.2 (19.1) 300 (65.8) 3.1 (0.7) 58.4 (12.4) 12.7 (3.56)
TDM4258g (n = 101) 80.9 (20.7) 457 (129) 3.53 (0.71) 28.4 (12.9) 8.51 (2.69)
TDM4374g (n = 105) 79.5 (21.1) 486 (141) 3.96 (0.96) 31.2 (10.9) 8.04 (2.97)
TDM4688g (n = 51) 75.6 (21.9) 431 (126) 4.02 (0.94) 41.2 (24.5) 9.17 (3.03)
Serum TT TDM3569g (n = 15) 110 (40.3) 1,144 (857) 9.1 (4.9) 50.7 (19.7) 4.90 (3.23)
TDM4258g (n = 101) 88.0 (30.2) 1,040 (1,030) 9.2 (10.9) 46.5 (58.4) 5.64 (6.30)
TDM4374g (n = 105) 89.9 (31.3) 1,150 (852) 9.38 (4.90) 43.2 (16.3) 4.55 (2.64)
TDM4688g (n = 51) 95.9 (32.3) 1,420 (1,390) 10.3 (6.8) 41.9 (16.2) 4.21 (2.43)
Analyte Study (no. of patientsa) Cmax at cycle 1 
(ng/mL)
Plasma DM1b TDM3569g (n = 15) 4.57 (1.33)
TDM4258g (n = 101) 5.35 (2.03)
TDM4374g (n = 105) 5.36 (2.56)
TDM4688g (n = 51) 5.42 (1.62)Cancer Chemother Pharmacol (2012) 69:1229–1240 1235
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EVects of HER2 ECD and baseline trastuzumab levels 
on response rates
The presence of baseline circulating HER2 ECD had no appar-
ent eVect on response rate (Fig. 2c). The serum TT concentra-
tion at baseline (pre-T-DM1 dose) measures trastuzumab in
circulation from prior trastuzumab treatment. TT concentra-
tions, post T-DM1 infusion, reXect trastuzumab from prior
treatment plus T-DM1 conjugate plus trastuzumab resulting
from T-DM1 deconjugation. As expected, TT AUC in cycle 1
was higher in patients with higher baseline trastuzumab con-
centrations; this also had no eVect on response rate (Fig. 2d).
Fig. 2 a Serum trastuzumab 
emtansine (T-DM1) area under 
the concentration–time curve 
(AUC) by response in patients in 
studies TDM4374g and 
TDM4258g. b Serum T-DM1 
maximum concentration (Cmax) 
by response in patients in studies 
TDM4374g and TDM4258g. 
c Baseline circulating human 
epidermal growth factor receptor 
2 (HER2) extracellular domain 
(ECD) by response in patients in 
studies TDM4374g and 
TDM4258g. d TT AUClast by 
response in patients in studies 
TDM4374g and TDM4258g. 
AUClast, area under the concen-
tration–time curve in the last 
sample drawn; PD progressive 
disease, PR partial response, 
SD stable disease, TT total 
trastuzumab (T-DM1 plus 
unconjugated trastuzumab)
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Exposure–safety relationship
In the phase I study [13], the MTD for T-DM1 monotherapy
q3w was established at 3.6 mg/kg on the basis of the DLT of
grade 4 thrombocytopenia that was observed in two of three
patients who received T-DM1 at 4.8 mg/kg. A dose-depen-
dent decline in platelet count was observed, with nadirs
observed around 8 days after T-DM1 administration and
recovery observed by about 15 days. Variability in the degree
of thrombocytopenia occurred among individual patients
[23]. Additionally, many patients had serum transaminase
increases based on National Cancer Institute Common
Terminology Criteria for Adverse Events v3.0 guidelines.
Across three studies (TDM3569g, TDM4258g, and
TDM4374g), laboratory data on serum transaminases were
available for 237 patients. Relative to the baseline, 19
patients had a grade 3 increase in serum AST, and one
patient had a grade 4 increase. Increases in serum ALT,
often a more speciWc indicator of hepatotoxicity than
increases in AST, were less common, with nine patients
having a grade 3 increase and one patient having a grade 4
increase. No adverse events potentially related to abnormal-
ities in hepatic synthetic function (i.e., hypoalbuminemia or
coagulopathy) were observed.
Given the increased frequency of these adverse events,
exposure–safety relationships with platelet, ALT, and AST
levels were examined. No obvious relationship between
T-DM1 exposure (by AUC quartiles) and thrombocytope-
nia or changes in serum concentrations of AST or ALT was
observed during the course of T-DM1 treatment across the
phase II studies (Fig. 3a–c). Similar results were observed
for circulating TT and DM1 exposure parameters (data not
shown). No obvious relationship between T-DM1 AUCs
and the presence or absence of grade 3 thrombocytopenia
was observed (mean AUC § standard deviation [SD],
369 § 78 day g/mL vs. 369 § 96 day g/mL, respectively).
Similarly, no correlations between T-DM1 AUCs and the
presence or absence of grade 3 increases in ALT (mean
AUC § SD, 397 § 168 day g/mL vs. 368 § 90  day g/
mL, respectively) or AST (mean AUC § SD, 391 § 136
day g/mL vs. 367 § 89 day g/mL, respectively) were
observed. Similar results were obtained for Cmax and Cmin
(data not shown).
Anti-therapeutic antibody response to T-DM1
Across the four studies, 13 of 286 patients treated with T-
DM1 3.6 mg/kg q3w were evaluable for ATA response.
ATA formation was observed in 4.5% (13 of 286) of these
patients. This response was conWrmed by competitive-bind-
ing immunodepletion with T-DM1 (data not shown). No
obvious patterns were observed in the PK, safety proWles,
or eYcacy outcomes of patients who developed antibodies
to T-DM1 compared with those who tested negative for
antibodies to T-DM1.
Discussion
Antibody–drug conjugates (ADCs) such as T-DM1 are
complex molecules composed of both small (DM1) and
large (trastuzumab) components. Therefore, a unique and
customized clinical pharmacology strategy to speciWcally
address patient safety and eYcacy following administration
of T-DM1 was employed; the results of this analysis are
reported here. Two key bioanalytical methodologies typi-
cally used for large and small molecule quantiWcation,
ELISA and LC–MS/MS, respectively, were used to mea-
sure the PK parameters of multiple analytes across phase I
and phase II studies. Validated PK assays were used to
measure T-DM1, TT, and DM1, while exploratory LC–MS/
MS assays were developed to measure linker/DM1-con-
taining catabolites, such as MCC-DM1 and Lys-MCC-
DM1, in plasma samples. Exposure–response (safety/
eYcacy) analyses were also conducted. Finally, the poten-
tial for immunogenicity was evaluated using a tiered
approach, in which ATA responses to all the molecular
components of the ADC were measured. Additional results
from the evaluation of clinical pharmacology of T-DM1 are
reported elsewhere and include a population PK assessment
of demographic and pathophysiologic covariates likely to
impact the clearance of T-DM1 [22], the potential for
T-DM1-induced QT interval prolongation [21], and the
potential for drug interaction [24, 25]. An integrated model-
ing and simulation strategy has also been implemented to
better understand the PK and pharmacodynamic relation-
ships with T-DM1 [22, 23, 26].
In the analysis reported here, a trend toward faster clear-
ance was observed at T-DM1 doses of ·1.2 mg/kg in the
phase I study TDM3569g; however, across doses ranging
from 2.4 to 4.8 mg/kg q3w, T-DM1 exhibited linear PK.
These results, though limited, suggest that the clearance of
T-DM1 occurs via dual mechanisms (i.e., target [HER2]
antigen–speciWc and nonspeciWc [e.g., Fc-mediated] mech-
anisms), similar to the clearance mechanisms observed with
other humanized antibodies [27]. Across studies, the PK
proWle of 3.6 mg/kg q3w, T-DM1 was characterized by
mean clearance values ranging from 7 to 13 mL/day/kg, a
volume of distribution limited to the plasma volume and a
t½ of approximately 4 days, which likely explains the obser-
vation in all four studies that repeated dosing of T-DM1
q3w did not result in any noticeable accumulation of T-DM1.
TT was found to have a slower clearance (approximately
3–6 mL/day/kg) and longer t½ (approximately 9–11 days)
compared with T-DM1. As T-DM1 is a mixture composed
of trastuzumab with 0–8 DM1 molecules, it is hypothesizedCancer Chemother Pharmacol (2012) 69:1229–1240 1237
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Fig. 3 a Platelet, b aspartate 
aminotransferase (AST), and 
c alanine aminotransferase 
(ALT) time courses (Wfth and 
ninety-Wfth percentiles) at each 
time point during the course of 
trastuzumab emtansine treat-
ment at 3.6 mg/kg every 3 weeks 
stratiWed by area under the con-
centration–time curve (AUC) 
quartile (Q) in studies 
TDM3569g, TDM4258g, and 
TDM4374g. Red bars, 95% con-
Wdence intervals; blue circles, 
patient values below the Wfth 
(platelets) or above the ninety-
Wfth (AST, ALT) percentile; 
black dashed line, cutoV for 
grade 3 or greater adverse event 
(>5 £ upper limit of normal 
(ULN) for AST and ALT; 
<50,000 platelet counts)
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that T-DM1 is mainly cleared by deconjugation (during which
higher drug-to-antibody ratio [DAR] species are converted
to lower DAR species and unconjugated trastuzumab) and
proteolytic degradation. The faster clearance of T-DM1 rel-
ative to TT may be explained by the combined clearance
mechanisms for T-DM1 [28].
The consistently low maximum systemic plasma DM1
concentrations (with an average »5 ng/mL at a T-DM1
dose of 3.6 mg/kg) demonstrated the stability of the T-DM1
linker MCC. Additionally, no evidence of DM1 accumula-
tion in plasma was observed after repeated dosing of T-DM1;
across all studies, maximum DM1 concentrations did not
exceed 25 ng/mL in individual patients after repeated
administration of T-DM1.
In an exploratory analysis of T-DM1 catabolites, low
concentrations of MCC-DM1 (<1.90–122 ng/mL) and
Lys-MCC-DM1 (<1.08–6.4 ng/mL) were observed. These
catabolites were also present in plasma, urine, and bile
samples obtained after the administration of radiolabeled
T-DM1 to rats, further conWrming the utility of the rat
model for assessing T-DM1 catabolism [29]. In the clinical
samples, no evidence of DM1, MCC-DM1, or Lys-MCC-
DM1 accumulation was observed after repeated dosing of
T-DM1. Given the nature of exploratory metabolite analy-
sis, it was not possible to comprehensively characterize the
kinetics of catabolite/metabolite formation; however, two
trends were apparent. In general, MCC-DM1 levels were
found to peak immediately after dosing, and a lag time was
associated with the formation of Lys-MCC-DM1, as higher
levels of this catabolite were observed at later time points.
PK serum samples with rich sampling were obtained in
the phase I study TDM3569g, and PK serum samples with
relatively sparse sampling were obtained from the phase II
studies TDM4258g, TDM4374g, and TDM4688g. In gen-
eral, the NCA and population PK approaches provided
good concordance of PK estimates [22]; however, a sys-
tematic bias appears to exist with the NCA approach for
AUC estimates. On average, the AUC was 20% higher
based on the NCA of the phase II studies compared with
that obtained using the population PK approach. This diVer-
ence was attributed partly to the sparse sampling, which
does not capture the distribution phase of T-DM1.
In a previously reported population PK analysis of
T-DM1 [22], there was no evidence to suggest that the
markers of liver function (e.g., AST, ALT, total bilirubin,
and albumin) and renal function (e.g., calculated creatinine
clearance) have a clinically meaningful eVect on the PK of
T-DM1. Further, in the exposure–safety analysis reported
here, T-DM1 total exposures (AUC) were compared
between patients with and without grade ¸3 ALT/AST
elevations after T-DM1 treatment, and no diVerences in
T-DM1 AUC values were observed. While the data presented
here suggest that hepatic and renal function are unlikely to
aVect the systemic exposure of T-DM1, it should be noted
that patients with moderate to severe liver impairment were
excluded in these trials and that the DM1 component of
T-DM1 is primarily metabolized and eliminated as DM1-
containing catabolites through the biliary route [29]. A clin-
ical study is needed to fully understand the relationship of
varying degrees of liver impairment on the PK, safety, and
appropriate dosing of T-DM1.
Dose-limiting, transient grade 4 thrombocytopenia was
observed with the T-DM1 regimen of 4.8 mg/kg q3w but
not with T-DM1 3.6 mg/kg q3w in a phase I study
(TDM3569g); no other dose level between 3.6 and 4.8 mg/
kg was tested. To determine whether there is a relationship
between T-DM1 exposure and platelet declines, platelet
counts in patients treated with T-DM1 3.6 mg/kg were
monitored in subsequent studies (TDM4258g and
TDM4374g). Similar to the changes in AST/ALT, no obvi-
ous trend was observed between platelet declines and total
exposure at a T-DM1 dose of 3.6 mg/kg q3w.
Because both of the phase II studies—TDM4258g and
TDM4374g—were conducted with a single T-DM1 dose
(MTD of 3.6 mg/kg in a q3w regimen), the relationship
between T-DM1 exposure and response (partial response,
stable disease, and progressive disease) was limited to a
narrow range of T-DM1 exposure. Other covariates, spe-
ciWcally baseline trastuzumab and baseline HER2 ECD
concentrations, did not aVect T-DM1 PK or response rates
signiWcantly in this patient population.
Overall, ATA formation was observed in 4.5% (13 of
286) of patients after repeated dosing of T-DM1 3.6 mg/kg
q3w across the four clinical studies. Although limited data
are available to date, there appears to be no obvious eVect
of ATA on the PK, safety, or eYcacy proWles of T-DM1.
The clinical signiWcance of antibody development against
T-DM1 is unknown; however, no obvious changes were
observed in the PK, safety proWles, or eYcacy outcomes of
patients who developed antibodies to T-DM1 compared
with patients who tested negative for antibodies to T-DM1.
In conclusion, the PK proWle (i.e., Cmax, AUC, t½, Vss,
and clearance) of single-agent T-DM1 (3.6 mg/kg q3w) is
predictable and well characterized, as demonstrated by its
consistency across the four clinical studies included in this
analysis. T-DM1 exposure at 3.6 mg/kg q3w does not cor-
relate with clinical responses, and eYcacy outcomes are not
aVected by circulating levels of HER2 ECD or residual
trastuzumab (from previous trastuzumab therapy). A rela-
tionship does not appear to exist between T-DM1 exposure
and the incidence of grade 3 thrombocytopenia or grade 3
elevations in levels of ALT or AST when given at this dose
regimen. The incidence of ATAs is low (4.5%) in patients
exposed to repeated doses of T-DM1.Cancer Chemother Pharmacol (2012) 69:1229–1240 1239
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